Company Encyclopedia
View More
name
GF CSI HK Innovative Drugs Industry ETF(QDII)
513120.SH
News
View More

Hansoh Pharma Licenses Hengrui’s Late-Stage Kidney Drug SHR6508 for China

Hansoh Pharmaceutical Group has signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals for SHR6508, a kidney drug in Phase III trials, for mainland China. The deal includes an upfront payment of RMB30 million, potential milestone payments up to RMB190 million, and tiered royalties. This complements Hansoh's nephrology portfolio, enhancing execution efficiency without affecting Hong Kong listing rules. Analysts rate Hansoh stock as a Buy with a HK$48.20 target.

Tip Ranks·
HK
03692
-0.69%
Tip Ranks·
HK
03692
-0.69%

Hansoh Pharma Adds Veteran Lawyer Yan Jia to Board, Bolsters Governance Committees

Hansoh Pharmaceutical Group has appointed Yan Jia, a veteran corporate lawyer, as an independent non-executive director effective December 26, 2025. Yan will also join the audit and ESG committees, enhancing governance and compliance. This move aims to strengthen board diversity and risk management in the pharmaceutical and capital markets environment. Yan's appointment aligns with Hong Kong listing rules, with an annual director’s fee of RMB360,000. The latest analyst rating for Hansoh stock (HK:3692) is a Buy with a HK$48.20 price target.

Tip Ranks·
HK
03692
-0.69%
Tip Ranks·
HK
03692
-0.69%

China Greenlights World’s First Dual-Immunotherapy for Colon Cancer Ahead of Surgery

China's drug regulator has approved Innovent Biologics' Daboxin® (Ipilimumab N01 Injection) for use with another monoclonal antibody as a pre-surgery immunotherapy for colon cancer. This is the world's first approved dual-immunotherapy neoadjuvant regimen for resectable stage IIB to III MSI-H/dMMR colon cancer. The treatment aims to improve outcomes and reduce chemotherapy reliance for patients less responsive to traditional treatments.

Yicai·
HK
01801
+0.06%
Yicai·
HK
01801
+0.06%

Innovent Biologics Wins NMPA Approval for First Domestic CTLA-4 Antibody TABOSUN in Colon Cancer

Innovent Biologics Inc. has received approval from China's NMPA for TABOSUN® (ipilimumab N01 injection), the first domestic CTLA-4 monoclonal antibody, for use with TYVYT® in treating stage IIB-III MSI-H/dMMR colon cancer. This marks the first global approval for such a neoadjuvant treatment, addressing a significant unmet need in China.

Reuters·
HK
01801
+0.06%
Reuters·
HK
01801
+0.06%
© 2025 Longbridge｜Disclaimer